Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients

Transplantation

Volumn 68, Issue 2, 1999, Pages 215-219

  Contreras, Juan L ^a   Eckhoff, Devin E ^a   Cartner, Samuel ^b   Frenette, Luc ^b   Thomas, Francis T ^a   Robbin, Michelle L ^c   Neville Jr , David M ^d   Thomas, Judith M ^a,b  

^a UAB Department of Surgery   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; IMMUNOTOXIN;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG SCREENING; DRUG TOLERABILITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE; WEIGHT REDUCTION;

ANIMALS; ANTIGENS, CD3; CAPILLARY LEAK SYNDROME; CYCLOSPORINE; IMMUNE TOLERANCE; IMMUNOTOXINS; ISLETS OF LANGERHANS TRANSPLANTATION; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIVER DISEASES; LIVER FUNCTION TESTS; MACACA MULATTA; MALE; METHYLPREDNISOLONE; TRANSPLANTATION CONDITIONING;

EID: 0033609509     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199907270-00009     Document Type: Article

References (13)

1. Thomas JM, Neville DM, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64: 124.
2. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
3. Contreras JL, Wang PX, Eckhoff DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 1998; 65: 1159.
4. Neville DMJ, Scharff J, Srinivasachar K. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 1992; 89: 2585.
5. Neville DMJ, Scharff J, Hu HZ, et al. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9. J Immunother Emphasis Tumor Immunol 1996; 19: 85.
6. Neville D Jr, Scharff J, Srinivasachar K. Anti-T cell immunotoxins: a look at post-endocytic receptor-mediated routing. J Controlled Release 1993; 24: 133.
7. Thrush GR, Lark LR, Clinchy BC, Vitetta ES. Immunotoxins: an update. Annu Rev Immunol 1996; 14: 49.
8. Pastan IH, Pai LH, Brinkmann U, Fitzgerald DJ. Recombinant toxins: new therapeutic agents for cancer. Ann NY Acad Sci 1995; 758: 345.
9. Vallera DA, Panoskaltsis-Mortari A, Blazar BR. Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin. Protein Eng 1997; 10: 1071.
10. Thompson J, Hu H, Scharff J, Neville DMJ. An anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 1995; 270: 28037.
11. Thomas FT, Ricordi C, Contreras JL, et al. Reversal of naturally occuring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999 (in press). Transplantation 1999; 67: 846.
12. Storek J, Gooley T, Siadak M, Besinger WI, Maloney DG, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705.
13. Smit WM, Rijnbeek M, van Bergen CA, Willemze R, Falkenburg JH. Generation of leukemia-reactive cytotoxic lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay. Bone Marrow Transplant 1998; 21: 553.